Cohesion a speculative buy say analysts:
This article was originally published in Clinica
Executive Summary
Biosurgical products company Cohesion Technologies has been given a speculative buy recommendation by Taglich Brothers, which specialises in companies with a market capitalisation of less than $250 million. Taglich gives the company, currently standing at $4.28, a three-year target price of $21.25. The New York company's products, which are used during surgery to stop bleeding, to prevent leakage of air or fluids, for the repair and attachment of tissues and to prevent the formation of adhesions after surgery.